scholarly journals COVID‐19 in lung transplant recipients: A case series from Milan, Italy

2020 ◽  
Vol 22 (6) ◽  
Author(s):  
Letizia Corinna Morlacchi ◽  
Valeria Rossetti ◽  
Lorenzo Gigli ◽  
Francesco Amati ◽  
Lorenzo Rosso ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Case Series ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

scholarly journals COVID-19 Disease in Lung Transplant Recipients: A Case Series

2021 ◽  
Vol 40 (4) ◽  
pp. S314
Author(s):  
L.L. Seijo ◽  
A. Perez ◽  
N. Thakur ◽  
A. Venado ◽  
L.E. Leard ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Case Series ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

scholarly journals Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19

2021 ◽  
Vol 2 (2) ◽  
pp. 229-245
Author(s):  
René Hage ◽  
Carolin Steinack ◽  
Fiorenza Gautschi ◽  
Susan Pfister ◽  
Ilhan Inci ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Clinical Laboratory ◽  
Invasive Mechanical Ventilation ◽  
Case Series ◽  
Outcome Data ◽  
Transplant Recipients ◽  
Retrospective Case ◽  
Laboratory Findings ◽  
Case Series Study ◽  
Lung Transplant Recipients

We report clinical features, treatments and outcomes in 18 lung transplant recipients with laboratory confirmed SARS-CoV-2 infection. We performed a single center, retrospective case series study of lung transplant recipients, who tested positive for SARS-CoV-2 between 1 February 2020 and 1 March 2021. Clinical, laboratory and radiology findingswere obtained. Treatment regimens and patient outcome data were obtained by reviewing the electronic medical record. Mean age was 49.9 (22–68) years, and twelve (67%) patients were male. The most common symptoms were fever (n = 9, 50%), nausea/vomiting (n = 7, 39%), cough (n = 6, 33%), dyspnea (n = 6, 33%) and fatigue (n = 6, 33%). Headache was reported by five patients (28%). The most notable laboratory findings were elevated levels of C-reactive protein (CRP) and lactate dehydrogenase (LDH). Computed Tomography (CT) of the chest was performed in all hospitalized patients (n = 11, 7%), and showed ground-glass opacities (GGO) in 11 patients (100%), of whom nine (82%) had GGO combined with pulmonary consolidations. Six (33%) patients received remdesivir, five (28%) intravenous dexamethasone either alone or in combination with remdesivir, and 15 (83%) were treated with broad spectrum antibiotics including co-amoxicillin, tazobactam-piperacillin and meropenem. Four (22%) patients were transferred to the intensive care unit, two patients (11%) required invasive mechanical ventilation who could not be successfully extubated and died. Eighty-nine percent of our patients survived COVID-19 and were cured. Two patients with severe COVID-19 did not survive.

Hepatitis E Virus Infection in Lung Transplant Recipients: A Case Series

2019 ◽  
Vol 51 (2) ◽  
pp. 376-379 ◽  
Author(s):  
G.P.L. Ambrocio ◽  
S. Aguado ◽  
J. Carrillo ◽  
R. Laporta ◽  
M. Lazaro-Carrasco ◽  
...  
Keyword(s):  
Virus Infection ◽  
Lung Transplant ◽  
Hepatitis E Virus ◽  
Case Series ◽  
Hepatitis E ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

Carbapenem-resistantKlebsiella pneumoniaein lung transplant recipients: A case series

2015 ◽  
Author(s):  
Priscila Cilene León Bueno Camargo ◽  
Silvia Vidal Campos ◽  
Felipe Xavier Melo ◽  
Ricardo Henrique de Oliveira Braga Teixeira ◽  
Paulo Manuel Pêgo-Fernandes
Keyword(s):  
Lung Transplant ◽  
Case Series ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature

2017 ◽  
Vol 32 (2) ◽  
pp. e13176 ◽  
Author(s):  
Jose Tiago Silva ◽  
Virginia Pérez-González ◽  
Francisco Lopez-Medrano ◽  
Rodrigo Alonso-Moralejo ◽  
Mario Fernández-Ruiz ◽  
...  
Keyword(s):  
Cytomegalovirus Infection ◽  
Lung Transplant ◽  
Case Series ◽  
Secondary Prophylaxis ◽  
Transplant Recipients ◽  
Review Of The Literature ◽  
Lung Transplant Recipients

scholarly journals Squamous cell carcinoma of the skin and voriconazole therapy in lung transplant recipients: a case series

2017 ◽  
Vol 47 (3) ◽  
pp. 228-235 ◽  
Author(s):  
Chin Fen Neoh ◽  
Gregory I. Snell ◽  
Bronwyn Levvey ◽  
Catherine Orla Morrissey ◽  
Monica A. Slavin ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lung Transplant ◽  
Case Series ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

Posttransplant Lymphoproliferative Disorder in Adult Lung Transplant Recipients: A Report on Twenty-Seven Patients.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4425-4425
Author(s):  
Sophie D. Stein ◽  
Jamal Misleh ◽  
Vivek Ahya ◽  
Robert Kotloff ◽  
Jason Christie ◽  
...  
Keyword(s):  
Surgical Resection ◽  
Lymphoproliferative Disorder ◽  
Lung Transplant ◽  
Radiation Treatment ◽  
Case Series ◽  
Complete Response ◽  
Transplant Recipients ◽  
Posttransplant Lymphoproliferative Disorder ◽  
Primary Treatment Modality ◽  
Lung Transplant Recipients

Abstract Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation. We report a case series on the diagnosis, treatment and outcome of PTLD in lung transplant recipients. From 1991 to 2006, 27 (5%) of the 502 lung transplant recipients at our institution developed PTLD. The median age at transplant was 51.5 years (range 21–65 years) and the median time from transplant to PTLD diagnosis was 33.7 months (range 1–174 months). Most cases had an elevated LDH (86%) and were EBV-positive (85%). Of the cases tested (n=14), 64% were monoclonal. PTLD was most commonly diagnosed in the lung (56%) and gastrointestinal tract (26%). Three patients were diagnosed at autopsy, while the remaining 24 received therapy. Eight patients were initially treated with reduced immunosuppression (RI) alone, but only 3 (38%) obtained a complete response (CR). Rituxan (R) was used alone (n=3) or in combination with RI (n=3) as initial therapy in six patients, four of whom obtained a CR. Five patients utilized RI +/− surgical resection as a primary treatment modality, all of whom achieved a CR. However, all of them relapsed and required further treatment. Of these five patients initially treated with RI +/− surgical resection, a CR was reestablished in 3 using rituxan alone (1/3), combined rituxan and reduced immunosuppression (1/3) and radiation treatment alone (1/3). The remaining five patients from the 24 patients receiving induction therapy for PTLD were given other treatments. With an average follow-up of 28 months (range 1-130 months), 81% of patients have died. However, only 18% of deaths were directly related to progressive PTLD. The remaining 17 deaths were due to: infection unrelated to PTLD treatment (15%), multi-organ failure (7%), graft failure not due to RI (30%), stroke (4%), and renal failure (4%). Most deaths can be attributed to disease specific and posttransplant complications rather than PTLD. Although an unfortunate diagnosis, PTLD is responsive to therapy, particularly reduced immunosuppression and rituximab.

Sign in / Sign up

Export Citation Format

Share Document